Posted by Michael Wonder on 02 Feb 2021
Mirum Pharmaceuticals announces completion of rolling NDA submission for maralixibat in Alagille syndrome
1 February 2021 - Maralixibat U.S. launch expected in second half of 2021, if approved.
Mirum Pharmaceuticals today announced it has completed submission of its rolling new drug application to the U.S. FDA for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
